Kathleen A Prodan is a notable inventor based in Buffalo Grove, IL (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of antiarrhythmic compounds. With a total of 3 patents to her name, her work has the potential to impact the treatment of cardiac conditions.

Latest Patents

One of her latest patents is titled "Process for antiarrhythmic 1,3-diazabicyclo[4.4.0]dec-2-en-4-ones." This invention relates to a process for preparing useful antiarrhythmic 1,3-diazabicyclo[4.4.0]dec-2-en-4-ones from 1-acyl-.alpha.-[2-[bis(1-methylethyl)amino]ethyl]-.alpha.-phenyl-2-piperidineacetamides. Additionally, it also involves the 1-acyl-.alpha.-[2-[bis(1-methylethyl)amino]ethyl]-.alpha.-phenyl-2-piperidineacetamides employed in this process. Another significant patent is for "Hexahydroindolizinones useful for treating cardiac arrhythmia." This invention focuses on hexahydroindolizinones, which serve as inhibitors of cardiac arrhythmias and platelet aggregation, making them useful in treating irregular heartbeat and preventing thrombus formation.

Career Highlights

Kathleen A Prodan has been associated with G.D. Searle & Company, where she has contributed her expertise in pharmaceutical innovation. Her work has been instrumental in advancing treatments for heart-related conditions, showcasing her dedication to improving patient outcomes.

Collaborations

Throughout her career, Kathleen has collaborated with notable colleagues such as Robert J Chorvat and Charles R Ellefson. These partnerships have likely enhanced her research and development efforts, leading to impactful innovations in the pharmaceutical industry.

Conclusion

Kathleen A Prodan's contributions to the field of pharmaceuticals through her patents demonstrate her commitment to innovation and improving healthcare. Her work continues to pave the way for advancements in the treatment of cardiac conditions.